Warfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complication

H. Malhi, B. Atac, A. K. Daly, Sanjeev Gupta

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Drug metabolism may be perturbed by genetically determined differences in the metabolic activity of cytochrome P450 enzymes. The authors encountered extensive bleeding in a patient receiving warfarin for anticoagulation after the introduction of celecoxib, an anti-inflammatory drug. As the CYP2C9 enzyme metabolises these drugs, it was determined whether variant alleles were responsible for altering warfarin handling. Genetic analysis established that the patient was a compound heterozygote with CYP2C9*2 and *3 variant alleles, which exhibit lower drug metabolising capacity and enhance susceptibility to drug toxicity.

Original languageEnglish (US)
Pages (from-to)107-109
Number of pages3
JournalPostgraduate Medical Journal
Volume80
Issue number940
DOIs
StatePublished - Feb 2004

Fingerprint

Celecoxib
Warfarin
Cytochrome P-450 Enzyme System
Hemorrhage
Pharmaceutical Preparations
Alleles
Heterozygote
Drug-Related Side Effects and Adverse Reactions
Anti-Inflammatory Agents
Cytochrome P-450 CYP2C9
Enzymes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Warfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complication. / Malhi, H.; Atac, B.; Daly, A. K.; Gupta, Sanjeev.

In: Postgraduate Medical Journal, Vol. 80, No. 940, 02.2004, p. 107-109.

Research output: Contribution to journalArticle

@article{196886ba00534692b721059579d3f58b,
title = "Warfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complication",
abstract = "Drug metabolism may be perturbed by genetically determined differences in the metabolic activity of cytochrome P450 enzymes. The authors encountered extensive bleeding in a patient receiving warfarin for anticoagulation after the introduction of celecoxib, an anti-inflammatory drug. As the CYP2C9 enzyme metabolises these drugs, it was determined whether variant alleles were responsible for altering warfarin handling. Genetic analysis established that the patient was a compound heterozygote with CYP2C9*2 and *3 variant alleles, which exhibit lower drug metabolising capacity and enhance susceptibility to drug toxicity.",
author = "H. Malhi and B. Atac and Daly, {A. K.} and Sanjeev Gupta",
year = "2004",
month = "2",
doi = "10.1136/pmj.2003.006478",
language = "English (US)",
volume = "80",
pages = "107--109",
journal = "Postgraduate Medical Journal",
issn = "0032-5473",
publisher = "BMJ Publishing Group",
number = "940",

}

TY - JOUR

T1 - Warfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complication

AU - Malhi, H.

AU - Atac, B.

AU - Daly, A. K.

AU - Gupta, Sanjeev

PY - 2004/2

Y1 - 2004/2

N2 - Drug metabolism may be perturbed by genetically determined differences in the metabolic activity of cytochrome P450 enzymes. The authors encountered extensive bleeding in a patient receiving warfarin for anticoagulation after the introduction of celecoxib, an anti-inflammatory drug. As the CYP2C9 enzyme metabolises these drugs, it was determined whether variant alleles were responsible for altering warfarin handling. Genetic analysis established that the patient was a compound heterozygote with CYP2C9*2 and *3 variant alleles, which exhibit lower drug metabolising capacity and enhance susceptibility to drug toxicity.

AB - Drug metabolism may be perturbed by genetically determined differences in the metabolic activity of cytochrome P450 enzymes. The authors encountered extensive bleeding in a patient receiving warfarin for anticoagulation after the introduction of celecoxib, an anti-inflammatory drug. As the CYP2C9 enzyme metabolises these drugs, it was determined whether variant alleles were responsible for altering warfarin handling. Genetic analysis established that the patient was a compound heterozygote with CYP2C9*2 and *3 variant alleles, which exhibit lower drug metabolising capacity and enhance susceptibility to drug toxicity.

UR - http://www.scopus.com/inward/record.url?scp=1542299177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542299177&partnerID=8YFLogxK

U2 - 10.1136/pmj.2003.006478

DO - 10.1136/pmj.2003.006478

M3 - Article

C2 - 14970301

AN - SCOPUS:1542299177

VL - 80

SP - 107

EP - 109

JO - Postgraduate Medical Journal

JF - Postgraduate Medical Journal

SN - 0032-5473

IS - 940

ER -